Elevation of Eosinophil Proportion After Pembrolizumab Increases the Risk of Immune‐Related Adverse Events in Patients With Bladder Cancer

ABSTRACT There is an unmet need to predict immune‐related adverse events (irAEs) in patients receiving immune checkpoint inhibitors. This study aimed to examine whether eosinophils can predict irAEs in metastatic urothelial carcinoma (mUC). In this multicenter cohort study, we retrospectively examin...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Kunihiro Odagiri, Yoshihiko Tasaki, Taku Naiki, Toshiharu Morikawa, Keitaro Iida, Yusuke Noda, Rika Banno, Teruki Isobe, Nobuhiko Shimizu, Maria Aoki, Yoshihisa Mimura, Yosuke Sugiyama, Takashi Nagai, Toshiki Etani, Shuzo Hamamoto, Ryosuke Ando, Noriyasu Kawai, Yoko Furukawa‐Hibi, Takahiro Yasui
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Wiley 2026-07-01
Edice:	Cancer Medicine
Témata:	bladder cancer eosinophil immune‐related adverse event pembrolizumab urothelial carcinoma
On-line přístup:	https://doi.org/10.1002/cam4.72072
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!